How to buy Zynex stock | 13.44

Zynex, Inc is a medical devices business based in the US. Zynex shares (ZYXI) are listed on the NASDAQ and all prices are listed in US Dollars. Zynex employs 283 staff and has a trailing 12-month revenue of around USD$68.7 million.

How to buy shares in Zynex

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Zynex. Find the stock by name or ticker symbol: ZYXI. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Zynex reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$13.44, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Zynex, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Zynex. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Zynex's share price?

Since the stock market crash in March caused by coronavirus, Zynex's share price has had significant positive movement.

Its last market close was USD$13.44, which is 11.76% up on its pre-crash value of USD$11.86 and 69.48% up on the lowest point reached during the March crash when the shares fell as low as USD$7.93.

If you had bought USD$1,000 worth of Zynex shares at the start of February 2020, those shares would have been worth USD$1,086.49 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,400.04.

Zynex share price

Use our graph to track the performance of ZYXI stocks over time.

Zynex shares at a glance

• Key figures

Information last updated 2020-11-23.

Latest market close	USD$13.44
52-week range	USD$7.51 - USD$29.73
50-day moving average	USD$14.6226
200-day moving average	USD$18.324
Wall St. target price	USD$25.75
PE ratio	44.7333
Dividend yield	N/A (0.88%)
Earnings per share (TTM)	USD$0.3

Buy Zynex shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Zynex stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Zynex, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Zynex price performance over time

Historical closes compared with the close of $13.44 from 2020-11-16

1 week (2020-11-19)	N/A
1 month (2020-10-30)	4.92%
3 months (2020-08-26)	N/A
6 months (2020-05-26)	N/A

1 year (2019-11-26)	N/A
2 years (2018-11-26)	N/A
3 years (2017-11-26)	N/A
5 years (2015-11-26)	N/A

Is Zynex under- or over-valued?

Valuing Zynex stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Zynex's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Zynex's P/E ratio

Zynex's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 45x. In other words, Zynex shares trade at around 45x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Zynex's EBITDA

Zynex's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$13 million.

The EBITDA is a measure of a Zynex's overall financial performance and is widely used to measure a its profitability.

Zynex financials

Revenue TTM	USD$68.7 million
Operating margin TTM	17.01%
Gross profit TTM	USD$36.8 million
Return on assets TTM	16.28%
Return on equity TTM	28.99%
Profit margin	14.9%
Book value	$1.563
Market capitalisation	USD$466.2 million

TTM: trailing 12 months

Shorting Zynex shares

There are currently 6.2 million Zynex shares held short by investors – that's known as Zynex's "short interest". This figure is 2.4% up from 6.0 million last month.

There are a few different ways that this level of interest in shorting Zynex shares can be evaluated.

Zynex's "short interest ratio" (SIR)

Zynex's "short interest ratio" (SIR) is the quantity of Zynex shares currently shorted divided by the average quantity of Zynex shares traded daily (recently around 1.0 million). Zynex's SIR currently stands at 6.13. In other words for every 100,000 Zynex shares traded daily on the market, roughly 6130 shares are currently held short.

However Zynex's short interest can also be evaluated against the total number of Zynex shares, or, against the total number of tradable Zynex shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Zynex's short interest could be expressed as 0.18% of the outstanding shares (for every 100,000 Zynex shares in existence, roughly 180 shares are currently held short) or 0.3387% of the tradable shares (for every 100,000 tradable Zynex shares, roughly 339 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Zynex.

Find out more about how you can short Zynex stock.

Zynex share dividends

We're not expecting Zynex to pay a dividend over the next 12 months.

Have Zynex's shares ever split?

Zynex's shares were split on a 1:40 basis on 16 December 2003. So if you had owned 40 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Zynex shares – just the quantity. However, indirectly, the new 3900% higher share price could have impacted the market appetite for Zynex shares which in turn could have impacted Zynex's share price.

Zynex share price volatility

Over the last 12 months, Zynex's shares have ranged in value from as little as $7.51 up to $29.73. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Zynex's is 0.9076. This would suggest that Zynex's shares are less volatile than average (for this exchange).

Zynex overview

Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. It offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation (TENS), and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and TENSWave, a dual channel TENS device. The company also supplies electrodes for the delivery of electrical current to the body and batteries for use in electrotherapy products; and distributes Comfortrac for cervical traction, JetStream for hot/cold therapy, and LSO Back Braces for lumbar support. In addition, it offers blood volume monitor, a non-invasive medical device for monitoring central blood volume for use in operating and recovery rooms to detect blood loss during surgery and internal bleeding during recovery. The company provides its products for use in pain management and control; and stroke and spinal cord injury rehabilitation. Zynex, Inc. sells its products through direct sales force primarily in the United States. The company was founded in 1996 and is headquartered in Englewood, Colorado.

Frequently asked questions

• What percentage of Zynex is owned by insiders or institutions?

  Currently 43.848% of Zynex shares are held by insiders and 36.08% by institutions.

• How many people work for Zynex?

  Latest data suggests 283 work at Zynex.

• When does the fiscal year end for Zynex?

  Zynex's fiscal year ends in December.

• Where is Zynex based?

  Zynex's address is: 9555 Maroon Circle, Englewood, CO, United States, 80112

• What is Zynex's ISIN number?

  Zynex's international securities identification number is: US98986M1036

• What is Zynex's CUSIP number?

  Zynex's Committee on Uniform Securities Identification Procedures number is: 98986M103